3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
3
Genitourinary
2
Gastrointestinal
2
Thoracic
1
Gynecologic
1
Dermatologic
1
Breast
1
Conditions
Pancreatic Neoplasms
8
Breast Neoplasms
4
Neoplasm Metastasis
3
Cholangiocarcinoma
3
Stomach Neoplasms
2
Ovarian Neoplasms
2
Head and Neck Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Biliary Tract Neoplasms
2
Uveal Melanoma
1
Urologic Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Adenocarcinoma Metastatic
1
Pancreatic Adenocarcinoma
1
Neoplasms
1
Mesothelioma
1
Melanoma
1
MMR-D/MSI-H Colorectal Cancers
1
Lung Neoplasms
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma
1
Anus Neoplasms
1
Interventions
pembrolizumab
29
Cetuximab
11
Nivolumab
10
Fluorouracil
8
Cyclophosphamide
8
Cisplatin
8
Carboplatin
8
fludarabine
7
atezolizumab
7
Blood Specimen Collection
7
cemiplimab
6
Radiotherapy
6
Drug Therapy
6
Immune Checkpoint Inhibitors
5
Gemcitabine
5
Paclitaxel
4
Docetaxel
4
Capecitabine
4
Biopsy
4
spartalizumab
3
avelumab
3
Surveys and Questionnaires
3
Pemetrexed
3
Oncolytic Virotherapy
3
Nicotine
3
Magnetic Resonance Spectroscopy
3
Irinotecan
3
Ipilimumab
3
Interleukin-2
3
Bortezomib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
niraparib
×
Gastrointestinal
×
Clear all
NCT04779151
2025-12-01
NIRADO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Terminated
51 enrolled
NCT05169437
2025-10-29
PAVO
Tempus AI
Phase 2
Terminated
22 enrolled
17 charts